A Case-control Study to Evaluate the Immunoinflammatory Effect of Prior Exposure to Anti-TNF Therapy in Patients With Ulcerative Colitis Starting Vedolizumab Therapy
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Vedolizumab (Primary)
- Indications Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
Most Recent Events
- 17 Dec 2020 Status changed from recruiting to discontinued as funding discontinued
- 17 Mar 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 17 Mar 2020 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.